Dose Escalation / Tolerability Study Design • Dose route: Oral, IV bolus, subcutaneous, intraperitoneal, intramuscular, dermal, topical • Dose used: Initiate starting dose based on in vitro cytotoxicity and/or published literature. If MTD is not determined industry standard dose escalation with increments for rapid (1.8x) or slow (1.15x) escalations are used. • Clinical Chemistry Panel: Albumin, Alkaline Phosphatase, Bilirubin/Total, BUN, Calcium, Chloride, Cholesterol, Protein/Total, Creatinine, Sodium, ALT, AST, Phosphorus, Potassium, Glucose, GGT, Uric Acid, Triglycerides • Hematology Parameters: Automated WBC, RBC, Hgb, Hct, Platelet Count, MPV, MCV, MCH, MCHC, and WBC • Gross Necropsy: To examine the organs for potential abnormalities and lesions • Histology / Immunohistochemistry: H&E and other specialized staining
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Dose Escalation / Tolerability Study Design• Dose route: Oral, IV bolus, subcutaneous, intraperitoneal, intramuscular, dermal, topical • Dose used: Initiate starting dose based on in vitro cytotoxicity and/or published literature. If MTD is not determined
industry standard dose escalation with increments for rapid (1.8x) or slow (1.15x) escalations are used. • Clinical Chemistry Panel: Albumin, Alkaline Phosphatase, Bilirubin/Total, BUN, Calcium, Chloride, Cholesterol,
Protein/Total, Creatinine, Sodium, ALT, AST, Phosphorus, Potassium, Glucose, GGT, Uric Acid, Triglycerides
• Hematology Parameters: Automated WBC, RBC, Hgb, Hct, Platelet Count, MPV, MCV, MCH, MCHC, and WBC
• Gross Necropsy: To examine the organs for potential abnormalities and lesions • Histology / Immunohistochemistry: H&E and other specialized staining
Related Documents
